Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem) examinations, including 3,209 performed on renally insufficient individuals.

Next Previous
Trial Profile

Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem) examinations, including 3,209 performed on renally insufficient individuals.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 21 May 2019 New trial record
  • 01 Apr 2019 Results assessing incidence of potential toxicity to gadoteric acid (Dotarem) within the local population, including those with renal insufficiency published in the European Radiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top